pharma · No medical condition. · Generalized Myasthenia Gravis
Lacuna Pharma Pty Ltd
Lacuna Pharma Pty is a pharma organization headquartered in Colmenar Viejo, AU. Primary therapeutic focus areas include No medical condition., Generalized Myasthenia Gravis, No therapeutic indication in the current trial
Phase 3 · small molecule · Acromegaly
Paltusotine (brand name PALSONIFY) is a small-molecule therapeutic developed by Lacuna Pharma Pty Ltd for the treatment of acromegaly, a rare endocrine disorder characterized by excessive growth hormone secretion. The drug is currently in Phase 3 clinical development, with an active randomized controlled trial (PATHFND
Internal code CRN00808-08
Paltusotine (brand name PALSONIFY) is a small-molecule therapeutic developed by Lacuna Pharma Pty Ltd for the treatment of acromegaly, a rare endocrine disorder characterized by excessive growth hormone secretion. The drug is currently in Phase 3 clinical development, with an active randomized controlled trial (PATHFNDR-2) evaluating safety and efficacy in subjects with non-pharmacologically treated acromegaly. Paltusotine has already achieved regulatory approval in the European Union, with marketing authorization granted by the EMA on 23 April 2026 under the product number EMEA/H/C/006636, marketed by Crinetics Pharmaceuticals Europe GmbH. The compound is classified within the systemic hormonal preparations therapeutic class (H01). Lacuna Pharma's development strategy focuses on addressing unmet needs in acromegaly management, particularly in patient populations inadequately controlled by existing pharmacological interventions. The Phase 3 PATHFNDR-2 trial represents a key milestone in establishing the clinical evidence base for paltusotine's efficacy and safety profile in this indication. The mechanism of action and specific molecular target remain not yet disclosed in available documentation.
Acromegaly is a rare but serious endocrine disorder with significant morbidity and mortality if left untreated or inadequately controlled. The disease impairs quality of life and increases cardiovascular and metabolic complications. Current treatment options include somatostatin receptor ligands (such as SIGNIFOR and SOMAVERT), growth hormone receptor antagonists, and dopamine agonists, yet a substantial proportion of patients remain inadequately controlled or experience treatment-limiting adverse effects. The competitive landscape includes established therapies such as SOMAVERT (pegvisomant), SIGNIFOR (pasireotide), and newer agents like SOGROYA and YSELTY, indicating an active market with ongoing innovation. Paltusotine's EMA approval in 2026 positions it as a new therapeutic option in this market segment. The Phase 3 PATHFNDR-2 trial specifically targets non-pharmacologically treated acromegaly patients, suggesting a potential niche for treatment-naïve or inadequately controlled populations. Commercial significance is underscored by the rarity of acromegaly, which typically commands premium pricing in specialty pharma markets. The drug's approval status in Europe and ongoing Phase 3 development indicate sponsor confidence in its clinical and commercial potential. Market relevance extends to both developed and emerging healthcare systems seeking improved acromegaly management options with favorable tolerability and efficacy profiles.
Drug Class: Systemic hormonal preparation (H01 therapeutic classification).
Modality: Small-molecule compound.
Mechanism of Action: Not yet disclosed.
Molecular Target: Not yet disclosed.
Route of Administration: Oral tablets (20 mg formulation).
Brand Name: PALSONIFY.
International Nonproprietary Name (INN): Paltusotine.
Related Therapies in Acromegaly: Somatostatin receptor ligands (SIGNIFOR, SOMAVERT), growth hormone receptor antagonists, dopamine agonists, and newer agents (SOGROYA, YSELTY, SKYTROFA).
First Approval: European Union approval granted 23 April 2026 by the EMA (EMEA/H/C/006636); marketed by Crinetics Pharmaceuticals Europe GmbH.
Patent Status: Not yet disclosed.
Also known as: Growth hormone excess, pituitary giant, somatotroph adenoma
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Acromegaly is an acquired disorder related to excessive production of growth hormone (GH) and characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations.
ClinicalTrials.gov lists 9 registered studies for Growth Hormone (AACT aggregate).
Phase breakdown: NA (6), PHASE3 (2), PHASE2/PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0019933), Orphanet — acromegaly, NCT00562796, NCT00966134, NCT01158612, NCT01540773, NCT04079010, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
PATHFNDR-2 trial active
Randomized, controlled, multicenter Phase 3 study evaluating safety and efficacy of paltusotine in subjects with non-pharmacologically treated acromegaly (NCT 2024-511924-15-00).
EMA approval
Paltusotine (PALSONIFY) approved by the European Medicines Agency (EMEA/H/C/006636) for marketing in the European Union.
The acromegaly treatment market includes multiple established and emerging competitors. SOMAVERT (pegvisomant, Pfizer) is a growth hormone receptor antagonist approved for acromegaly management. SIGNIFOR (pasireotide) represents a somatostatin receptor ligand class therapy. Newer agents include SOGROYA and YSELTY, indicating ongoing innovation in the space. INCRELEX is listed as a competitor under Lacuna Pharma Pty Ltd, suggesting potential portfolio overlap or related indications. Other agents such as ORGOVYX, THYROGEN, GENOTROPIN GOQUICK, ARX GANIRELIX, NGENLA, CETROTIDE, and SKYTROFA (lonapegsomatropin, Ascendis Pharma) represent the broader endocrine and hormonal treatment landscape, though specific acromegaly indications for each are not detailed in available facts. Paltusotine's 2026 EMA approval positions it as a newcomer to the market with potential differentiation based on mechanism of action (not yet disclosed), oral formulation, and efficacy/safety profile to be established by the ongoing Phase 3 PATHFNDR-2 trial. The competitive positioning will depend on comparative efficacy, safety, tolerability, and pricing relative to established standards of care.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| INCRELEX | Lacuna Pharma Pty Ltd | — | approved |
| ORGOVYX | — | — | approved |
| THYROGEN | Sanofi-aventis Healthcare Pty Ltd | — | approved |
| SOMAVERT | Pfizer Australia Pty Ltd | — | approved |
| GENOTROPIN GOQUICK | Pfizer Australia Pty Ltd | — | approved |
| SIGNIFOR | — | — | approved |
| SOGROYA | — | — | approved |
| ARX GANIRELIX | Alphapharm Pty Ltd | — | approved |
| NGENLA | Pfizer Australia Pty Ltd | — | approved |
| CETROTIDE | Merck KGaA, Darmstadt, Germany | — | approved |
| YSELTY | — | — | approved |
| SKYTROFA (PREVIOUSLY LONAPEGSOMATROPIN ASCENDIS PHARMA) | — | — | approved |
| PEGVISOMANT | — | Growth hormone receptor antagonist | Approved |
| PASIREOTIDE PAMOATE | — | Somatostatin receptor 2 agonist | Approved |
| OCTREOTIDE ACETATE | — | Somatostatin receptor agonist | Approved |
| LANREOTIDE ACETATE | — | Somatostatin receptor 2 agonist | Approved |
| BROMOCRIPTINE MESYLATE | — | D2-like dopamine receptor agonist | Approved |
| PASIREOTIDE | — | Somatostatin receptor 5 agonist | Phase 3 |
| PALTUSOTINE | — | Somatostatin receptor 2 agonist | Phase 3 |
| OCTREOTIDE | — | Somatostatin receptor agonist | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
European Union: Paltusotine (PALSONIFY) received marketing authorization from the European Medicines Agency on 23 April 2026 (EMEA/H/C/006636). Marketing authorization holder: Crinetics Pharmaceuticals Europe GmbH.
United States FDA: Regulatory status not yet disclosed.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
Development Status: Phase 3 clinical trial (PATHFNDR-2) is currently active, evaluating safety and efficacy in non-pharmacologically treated acromegaly patients.
Patent and Exclusivity: Not yet disclosed.
Paltusotine is a small-molecule therapeutic indicated for the treatment of acromegaly, a rare endocrine disorder characterized by excessive growth hormone secretion. It is specifically being evaluated in Phase 3 trials for non-pharmacologically treated acromegaly patients.
Yes, paltusotine (brand name PALSONIFY) received marketing authorization from the European Medicines Agency on 23 April 2026 (EMEA/H/C/006636). Regulatory status in the United States, Japan, and China is not yet disclosed.
Paltusotine is developed by Lacuna Pharma Pty Ltd. In the European Union, the marketing authorization holder is Crinetics Pharmaceuticals Europe GmbH.
The mechanism of action and specific molecular target of paltusotine are not yet disclosed in available documentation.
Paltusotine is a small-molecule compound classified within the systemic hormonal preparations therapeutic class (H01).
Paltusotine is administered as an oral tablet formulation, with a 20 mg strength referenced in the clinical program.
PATHFNDR-2 is a randomized, controlled, multicenter Phase 3 study evaluating the safety and efficacy of paltusotine in subjects with non-pharmacologically treated acromegaly (NCT 2024-511924-15-00). Results have not yet been reported.
The Phase 3 PATHFNDR-2 trial focuses on subjects with non-pharmacologically treated acromegaly, which may include treatment-naïve patients or those inadequately controlled by existing therapies.
Established competitors include SOMAVERT (pegvisomant, Pfizer), SIGNIFOR (pasireotide), SOGROYA, YSELTY, and SKYTROFA (lonapegsomatropin, Ascendis Pharma). Each represents different therapeutic classes or mechanisms within acromegaly management.
The expected FDA approval timeline is not yet disclosed. Regulatory status in the United States remains unknown.
Paltusotine is classified as a systemic hormonal preparation (H01) according to therapeutic classification systems.
Paltusotine is approved and available in the European Union under the brand name PALSONIFY as of 23 April 2026. Availability in other regions depends on regulatory approval status, which is not yet disclosed.
Acromegaly is a rare endocrine disorder caused by excessive growth hormone secretion, typically from a pituitary adenoma. It results in abnormal growth of hands, feet, and facial features, and carries increased risk of cardiovascular and metabolic complications.
Combination therapy studies are not mentioned in the available facts. Future development plans are not yet disclosed.
Patent status and exclusivity information for paltusotine are not yet disclosed.
No partner or license type information is disclosed for the paltusotine program (CRN00808-08).
CRN00808-08 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Positioning: Lacuna Pharma's development of paltusotine reflects a focused strategy in rare endocrine disorders, specifically acromegaly. The EMA approval in April 2026 provides early validation of the drug's clinical profile and regulatory pathway, potentially supporting future approvals in other jurisdictions.
Clinical Development: The Phase 3 PATHFNDR-2 trial targets non-pharmacologically treated acromegaly, a patient population that may represent either treatment-naïve patients or those inadequately controlled by existing therapies. This positioning suggests potential for a distinct clinical niche rather than direct head-to-head competition with established first-line agents.
Competitive Implications: The acromegaly market remains active with multiple therapeutic options and ongoing innovation (SOGROYA, YSELTY, SKYTROFA). Paltusotine's oral small-molecule formulation may offer convenience advantages over injectable or infusion-based competitors, though comparative efficacy and safety data are required to establish true competitive differentiation.
Regulatory Pathway: Early EMA approval suggests a potentially favorable benefit-risk profile. Future catalysts include Phase 3 trial readout, potential FDA submission and approval, and label expansion studies in additional patient populations or combination therapies.
Commercial Considerations: Acromegaly is a rare disease with limited patient populations, typically supporting premium pricing models. Market penetration will depend on clinical evidence, reimbursement decisions, and physician adoption relative to established standards of care.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.